MétaCan
Menu
← Back to cohort

Initial Results of an Ex Vivo Microfluidic Cis-Coculture Csra to Predict Response for Myeloma Patients

2014· article· en· W2553643169 on OpenAlexaff
Chorom Pak, Natalie S. Callander, Edmond W. K. Young, B Titz, KyungMann Kim, Kenny Chng, Shigeki Miyamoto, David J. Beebe

Bibliographic record

VenueBlood · 2014
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsUniversity of Toronto
Fundersnot available
KeywordsBortezomibMultiple myelomaEx vivoIn vivoTumor microenvironmentCancer researchIn vitroCancerCell cultureProteasome inhibitorImmunologyMedicineChemistryBiologyInternal medicineTumor cellsBiochemistry

Abstract

fetched live from OpenAlex

Abstract In vitro chemosensitivity and resistance assays (CSRAs) test primary tumor cells’ response to chemotherapeutic drugs. The goal of CSRAs is to potentially direct therapy based upon in vitro response. This is in contrast to empiric therapy of cancer patients where therapy is based on clinical trial evidence and the likelihood of patient response. However, most previous CSRAs have been unsuccessful; this may be because they employ tumor cells in mono-culture. increasing evidence indicates that heterogeneity in tumor cell biology and microenvironment and the interaction between the two play essential roles in regulating drug response. In addition, many of these assay and culture systems require more tumor cells per condition than can be obtained from every patient. Furthermore, coculture systems in the past often cultured tumor and non-tumor cells from different patients (trans-coculture). Therefore, a CSRA capable of being performed for all patients while incorporating both tumor cells and non-tumor microenvironmental cells from the same patient is needed. Here, by using a microfluidic ex vivo system requiring only thousands of cells per condition, we analyzed patient CD138+ multiple myeloma (MM) cells in either microfluidic mono-culture (MicroMC) or cis-coculture (MicroC3) with their own CD138- non-tumor mononuclear cells. The MM CD138+ cells were then exposed to varying doses of bortezomib, a clinical proteasome inhibitor, for 24 hours. An in-house software program, J’experiment, was used to calculate live fractions of the tumor cells. Because plasma concentrations of bortezomib peak at 100 nM, the change in live fraction was calculated from the 0 and 100 nM dose of bortezomib. Using k-means and Gaussian mixture clustering techniques, MicroC3 responses could be grouped into two distinct data clusters which correctly identified 17/17 patients as either clinically responsive (7) or non-responsive (10). On the other hand, responses measured in MicroMC could not be unambiguously separated into clinical response groups. Thus, MicroC3 accurately identified MM patient responses as either responsive or non-responsive to bortezomib-containing therapy. Further development of MicroC3 as a CSRA with the ability to rapidly identify chemosensitive or resistant cancer patients will enable more personalized therapeutic decisions. Disclosures Beebe: Bellbrook Labs, LLC: Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.003

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.305
Teacher spread0.287 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueBlood→Same topicMultiple Myeloma Research and Treatments→French-language works237,207→